Wentworth Kerry 4

What Happened
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), exercised 63,000 options on June 23, 2026 (paying ~$2.93 per share, total cost $184,590) and the 63,000 shares acquired were sold the same day in an open‑market transaction for a weighted‑average price of $6.02 per share, totaling approximately $379,191. The filing also reports the corresponding derivative (the option) being converted/terminated in connection with the exercise.

Key Details

• Transaction date: 2026-06-23.
• Exercise: 63,000 shares at $2.93 per share paid = $184,590 (code M).
• Sale: 63,000 shares sold at weighted‑avg $6.02 = $379,191 (code S); individual sale prices ranged $6.00–$6.08 (footnote F2).
• The sales were made pursuant to a prearranged 10b5‑1 plan dated December 4, 2025 (footnote F1).
• Vesting note: the option vests 25% after one year from Aug 29, 2022, then monthly over 36 months (footnote F3).
• Shares owned after the transaction: not specified in this filing.
• Filing: Report filed 2026-06-24 covering the 6/23/2026 transactions (no late‑filing flag indicated).

Context
This was effectively a cashless exercise: Wentworth paid the exercise cost to convert options into shares and sold those shares the same day under a 10b5‑1 plan. Such exercises followed by immediate sales are commonly routine (e.g., to cover exercise/tax costs) and do not, by themselves, indicate a change in insider sentiment.